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ABSTRACT--Objectives. This prospective study was undertaken to evaluate the effects of 
transurethral ultrasound-guided laser-induced prostatectomy [TULIP] on urodynamic, 
symptomatic, and prostate volume parameters as well as serum prostate-specific antigen. 
Methods. The TULIP procedure was performed in 33 patients with benign prostatic hy- 
perplasia with a mean age of 66 years. Patients were evaluated by pressure-flow studies, 
prostate volume measurement by transrectal ultrasound, and the American Urological 
Association (AUA) symptom score. 
Results. At 5-month follow-up, laser prostatectomy has resulted in an increased maxi- 
mum flow rate from 6.6_+0.5 to 11.2+0.6 mL/s and in an objectively proven relief of 
the urodynamic obstruction, as is evident by a decrease of the average value of the ure- 
thral resistance parameter URA and the detrusor pressure at maximum flow rate from 
38.3+2.7 to 21.3+ 1.3 cm water and from 62.7_+4 to 38.9+2.1 cm water, respec- 
tively. Symptomatic improvement is evident from a decrease in the AUA symptom score 
from 20.4 at baseline to 8.8 at 6-month follow-up. Although the total symptom score did 
not change significantly between 6 months and 1 year follow-up, the score of the symp- 
tom "weak stream" was significantly higher again at 12 months follow-up. 
Conclusions. The TULIP procedure is a urodynamically and symptomatically effective 
treatment. Conclusions about the durability of this treatment modality should be made 
with reservations. 
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Although most side-firing fibers are operated under 
direct vision, transurethral u l trasound-guided 
laser-induced prostatectomy (TULIP) is a technol- 
ogy that utilizes the side-firing principle under ul- 
trasound guidance. Via the transurethral route, the 
prostate is irradiated in a systematic way by a 
Nd:YAG laser source. 
This study was initiated to determine objectively 
the effects of this treatment modality on urody-- 
namic (urethral resistance) parameters, ymptom 
score, prostate volume, and serum prostate-spe- 
cific antigen (PSA). 
Data on symptomatic changes and changes in 
uroilowmetry values have been reported previously 
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for the TULIP procedure 2 and for visual laser abla- 
tion of the prostate (Viva, P).3,4 This study addresses 
changes in urethral resistance parameters after 
laser treatment for benign prostatic hyperplasia. 
MATERIAL AND METHODS 
PROCEDURE 
The TULIP system consists of an ultrasound im- 
ager and a 20 F transurethral probe that incorpo- 
rates a side-firing laser window positioned between 
two halves of a split ultrasound transducer. The 
TULIP probe is enclosed in a sleeve that incorpo- 
rates a balloon at its distal end. The balloon, which 
is filled and pressurized with sterile water, creates a
constant standoff from the tissue, stabilizes the sys- 
tem in the prostatic urethra, and decreases blood 
flow in the tissue. The 2 atmospheres of balloon 
pressurization are not associated with a dilation ef- 
fect. 5 The part of the probe that contains the laser 
window and the ultrasound transducer can be 
moved in a longitudinal and rotational fashion in 
the working window, which is created by the pres- 
surized balloon. The TULIP system was coupled to 
a 60 W Nd:YAG laser set at 40 W. The procedure 
has been described in detail by McCullough et al. 2 
In the present series 48 F balloons were used in all 
but 2 patients. Laser passes were initiated with a 5- 
second dwelling time at the bladder neck followed 
by a pull rate of 1 minis. Laser passes were termi- 
nated when the thickness of the prostatic tissue 
became 1 cm on the ultrasound imager. An average 
of 8 to 10 passes in different positions were made 
per patient. After the procedure, cystoscopy was 
performed to check for blanching of the prostatic 
urethra, and a suprapubic atheter was inserted. 
STUDY PARAMETERS 
Prostate volume was measured by transrectal ul- 
trasound with a 7 MHz Bruel and Kjaer multiplane 
sector scanning probe. The planimetric technique 
of volume measurement was used at baseline and 3 
months  post - t reatment .  6 Serum PSA levels 
(Hybritech-Tandem) were measured at baseline 
and 24 and 48 hours, 1 week, and 3 months post- 
operatively. Prostate biopsies were performed in all 
men with PSA more than 10 ng/mL and in all men 
who had hypoechogenic lesions on transrectal ul- 
trasound. No prostate cancers were detected in the 
men included in this study. 
The American Urological Association (AUA) 
symptom index was determined at baseline and 3, 
6, and 12 months post-treatment, r 
The postvoid residual urine volume (in milli- 
liters) was measured by transabdominal ultrasound 
using an Aloka machine with a 3.5 MHz handheld 
probe using the formula: re/6 x ( 
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508 UROLOGY ~ /OcToBER d994 / 
:bongos in serum prostate-specific 
values in relation to the trans- 
'altrasound-guided laser-induced 
-ostatectomy procedure * 
Prostate-Specific 
Antigen (ng/mL) 
~{rat ,ve  4.5 + 0.9 (0.8-2755) 
~stoperat ive  61.94_- 18.7 (t .6 354) 
~stoperat ive  28.9 -I- 6 .8  (1 .4-136) 
~90stoperat ive  10.2 +_ 1.9 (1.0-33.8) 
{hs postoperative 2.9 + 0.5 (0.4-10.3) 
~ eans + standard error with ranges in parentheses, 
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PECIFIC ANTIGEN 
:t of laser treatment of the prostate on 
PSA value is shown in Table I. There is 
a 14-fold increase in serum PSA after 24 
the 3-month follow-up, the serum PSA 
rage dropped below the baseline value. 
VOLUME {rA~E 
!!e effects of laser treatment on prostate volume 
~Summarized in Table II. The average prostate 
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if conical defect in the prostatic urethra was 
~in only 8 men after the procedure. 
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FIGURE 1. Effect of transurethrel ultrasound-guided 
laserqnduced prostatectomg procedure on pressure- 
flow parameters, Values for detrusor pressure at maxi- 
mum flow rote ore plotted in Abrams-Criffiths nomo- 
gram. Closed circles indicate pretreatment meas- 
urements and open squares indicate post-treatment 
measurements. 
well with residual urine volumes of 0, 60, and 74 
mL, respectively. The obstruct ion parameters 
Pdet.Qmax nd URA decreased significantly. On aver- 
age the URA value was in the nonobstructed range 
at the 3-month urodynamic follow-up. The bladder 
contraction strength parameter Wma x showed a 
small but significant decrease. The flow rate in- 
creased significantly. However, the residual urine 
volume did not change significantly. If, however, 
the residual urine volumes of the 2 patients who 
were in retention preoperatively and the 1 patient 
who did not undergo invasive urodynamic testing 
at 3 months are included, there is a significant 
(p = 0.02) decrease of the average (+_ SE) residual 
urine volume from t63 _+ 71 to 57 +_ 18 mL. 
When Pd~.Q~x is plotted in the Abrams-Griffiths 
nomogram (Fig. 1), it becomes clear that 12 and 4. 
TABLE II. Effects of transurethral ultrasound-guided laser-induced 
prostatectomy procedure on urodynamic (n = 30), symptomatic 
(n = 32), and prostate volume parameters (n = 33) at 3 months follow-up* 
Parameter Baseline 3 Month Follow-up p Value 
AUA 7 index 21.3 (5 35) 10.7 (2-23) 0.0001 
Prostate volume (crn 3) 56 (20-tl  8) 51 {I 5-125) NS 
PdeLQmax {cm H20) 63 (26-110) 39 (18-58) 0.0001 
Maximal flow (mL/s) 6.6 (3.7--15) 11.2 (4.4-20.4) 0.0001 
Residual urine {mL) 87 {0-330) 58 (0-400) NS 
URA (cm I-I~O) 38 (17-78) 21 (11-35) 0.0001 
W .... (W/m 2) 9.8 (3.4-16.6) 8.6 (4.3- t 4.6) 0.04 
K~v: NS = not significant. 
*Va lues  are means with ranges in pa*entheses. 
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TABLE 1tl. Effects of transurethral ultrasound- 
guided laser-induced prostatectomy procedure 
on individual symptoms and total AUA symptom 
score at 3 and 6 months follow-up * 
Follow-up 
3 Months 6 Months 
Symptoms Baseline (n = 26) (n = 26) 
Emptying 3.1 (0-5) 1.4 (0-5) 1.2 (0-5) 
Frequency 3.4 (0-5) 2.3 (0-5) 1.7 (0-5) 
Intermittency 2.8 (0-5) 0.8 (0-4) 1.0 (0-5) 
Urgency 2.6 (0 5) 2.2 (0 5)* 1.5 (0-5) 
Weak stream 4,2 (2-5) 1.3 (0-5) 1.3 (0 5) 
HesitancY 1.5 (0-5) 0.3 (0-2) 0.4 (0 4) 
Nocturia 2.7 (1-5) 2.0 (0- 5) 1.8 (0-4) 
AUA-7 index 20.4 (5-35) 10.3 (2-23) 8.8 [1-26) 
*Values are means with ranges in parentheses. All changes in scores ate statisti- 
cally significant (p <0.05) when compared with baseline, except that marked with 
an asterisk. 
patients, respectively, move from the obstructed 
area to the equivocal area and from the obstructed 
to the nonobstructive area. Three patients move 
from the equivocal to the nonobstructed area. Four 
and 7 patients, respectively, remain in the ob- 
structed and in the equivocal areas. Preoperatively, 
20 patients were in the obstructive and 10 in the 
equivocal range, whereas at the 3-month Urody- 
namic follow-up, 4 men remained in the obstruc- 
tive area and 19 and 7 were in the equivocal and 
nonobstructive areas, respectively. 
The average (_+ SE) residual urine volumes at 6 
and 12 months were 34 _+ 12 and 35 _+ 12 mL, re- 
spectivelY; these values were not significantly dif- 
ferent from the values at the 3-month follow-up. 
SYMPTOMS 
Baseline and 3-month symptom score data were 
available for 32 patients (Table II; 1 patient did not 
complete a symptom score preoperatively). There 
was no correlation between the percentage change 
in urethral resistance (URA) and the percentage 
change in the total symptom score (r = 0.13; p = 
0.537) at the 3-month follow-up. 
The baseline, 3- and &month follow-up symp- 
tom data of the 26 patients who have completed a 
minimum follow-up of 6 months are summarized 
in Table III. Laser treatment, of the prostate results 
in a significant improvement of the individual 
symptoms and the total score on the AUA-7 index. 
It takes between 3 and 6 months forthe symptom 
"urgency' I to improve significantlY. This reflects the 
severe irritative symptoms that are sometimes en- 
countered in the first weeks after the procedure. 
In 17 patients the 12-month follow-up has been 
reached. The total score and the scores for the in- 
dividual symptoms were not signifi 
from the &months data, except fo 
"weak stream" which showed an in 
to 1.6 (p = 0.03). 
REPEAT URODYNAMICS AFTER .3 MONTE 
AND RETREATMENT 
At 6 months, the syrnptom inde: 
again significantly in 1 patient, b 
urine volume in this patient was 0 
to 80 mL preoperatively At 12 m 
urodynamic study was done in 1 l 
of a deteriorating symptora score : 
ing residual urine volume. The urc 
showed an increased urethral re 
transurethral resection of the pt 
was subsequently performed in 
TURP was performed in 1 additi 
the 12-month follow-up. This pal 
macroscopic hematuria due to his 
tic hyperplasia nd underwent a -[ 
the fact that the AUA symptom:  
low. 
COMPLICATIONS 
Few complications were seen. 
had to be abandoned in 1 patient, 
cluded in this series, because of a 
the TULIP probe. Water intoxicati< 
in any of the patients. No blood tr', 
necessary. In 1 patient a transureth 
to be inserted for bladder irrigal 
bleeding blocking the thin supra 
This Catheter was removed again 3 
patient needed intravenous antibi~ 
septicemia. In another patient drug 
due to the routinely administered 
urethral strictures have been foum 
up. No patient has complained of i 
COMMENT 
There is still a paucity of articl 
results of laser treatment of the pr 
has compared the results of TURP 
and 13 patients, respectively, and: 
bte improvements in symptom s 
mum flow rate at 3 and 6 months t
fold increase in serum PSA was r 
treatment. In ttie present series a 
was found on average. Norris et al." 
erage increase in flow rate from 
after visual laser ablation of the p 
laugh et al. 2 have reported on 
6 months follow-up in 63 patier 
the TULIP procedure. In these m, 
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n score 12 decreased from 18.8 + 5 
he maximum flow rate increased 
[1.9 +_ 4.7 mL/s. These results are 
: results of the present series. 
tta on changes in urethral resis- 
e-flow parameters in relation to 
ay are available in the literature• 
Jy, the average (+_ SE) value of the 
rowed a decrease from 38.3 + 2.7 
water, which represents an aver- 
t the clearly obstructed range 
ted range. These improvements 
when the preoperative and post- 
for PdecQmax are plotted in the 
aomogram (Fig. 1). These results 
er treatment of the prostate is 
7on a urodynamic point of view. 
! the average change in the value 
;istance parameter is comparable 
:nt seen in a group of 29 TURP 
:d by Rollema and van Mastrigt, 13 
erage change from 41 to 16 cm 
.meter URA. 
y, there is a clear effect as well. 
E) AUA symptom score had de- 
, _+ 1.4 to 10.7 + 1.0 at 3 months 
change is comparable to the 
Bar ry  et al.  r in a group of 27 
ao showed a decrease from 17.6 
post-TURR A further decrease to 
ollow-up, which is found in the 
nainly due to an improvement of
;ency, which reflects the late in-  
sometimes severe irritative syrup- 
postoperative p riod• Seventeen 
en followed for 12 months or 
)res for the individual symptoms 
;ignificantly between 6 and 12 
• the score of the symptom "weak 
creased front 0.9 to 1.6 on aver- 
ais series show that a significant 
.te volume as measured by trans~ 
l is not necessary to achieve a 
and symptomatic improvement. 
ages in prostate volume may not 
Lhe effect on the prostate because 
increase in serum PSA 24 hours 
t, which indicates that consider- 
;e has taken pIace. Furthermore, 
PSA at the 3-month follow-up 
he baseline value, which may in- 
loss has taken place. The TULIP 
effective treatment for benign 
asia. The long-term results have 
to be awaited. The fact that the score of at least 
one symptom, that is, "weak stream" shows dete- 
rioration at the 12-month follow-up indicates that 
further studies of the durability of the effect of 
laser treatment of the prostate are certainly neces- 
sary. 
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